C07C 311/44
Having the nitrogen atom of at least one of the sulfonamide groups
Official title: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07C311/44 (Having the nitrogen atom of at least one of the sulfonamide groups) appears on 123 US grants and 123 published applications in this corpus.
Search patents in C07C- Granted patents
- 123
- Published applications
- 123
- Assignees
- 121
- Inventors
- 523
- Latest grant
- 24 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 2 | 0 |
| 1978 | 6 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 5 | 0 |
| 2000 | 4 | 0 |
| 2001 | 4 | 1 |
| 2002 | 5 | 1 |
| 2003 | 7 | 6 |
| 2004 | 0 | 10 |
| 2005 | 3 | 10 |
| 2006 | 2 | 4 |
| 2007 | 8 | 5 |
| 2008 | 3 | 3 |
| 2009 | 3 | 6 |
| 2010 | 4 | 8 |
| 2011 | 4 | 4 |
| 2012 | 2 | 5 |
| 2013 | 5 | 2 |
| 2014 | 4 | 8 |
| 2015 | 6 | 7 |
| 2016 | 3 | 5 |
| 2017 | 5 | 4 |
| 2018 | 2 | 4 |
| 2019 | 5 | 5 |
| 2020 | 6 | 5 |
| 2021 | 1 | 4 |
| 2022 | 5 | 5 |
| 2023 | 2 | 5 |
| 2024 | 3 | 2 |
| 2025 | 2 | 4 |
| 2026 | 2 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Benzenesulfonamide derivatives and uses thereof24 Feb 2026US 12,559,454 B22692372 Ontario, Inc.
- Methods and compositions for targeting Tregs using CCR8 inhibitors17 Feb 2026US 12,552,753 B2Nanjing Immunophage Biomedical Co., Ltd.
- Phenylalanine-based LAT1 inhibitors and uses thereof30 Sep 2025US 12,427,124 B1Maxymune Therapeutics, Inc.
- Small molecule inhibitors of TEAD transcription factors7 Jan 2025US 12,187,722 B2The General Hospital Corporation
- Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction22 Oct 2024US 12,122,742 B2Rutgers, The State University of New Jersey
- Phenylalanine-based lat1 inhibitors and uses thereof6 Nov 2025US 2025/0339388 A1Maxymune Therapeutics, Inc.
- Substituted Phenylbenzenesulfonamide Derivatives and Uses Thereof6 Nov 2025US 2025/0340510 A1Nine Square Therapeutics Corporation
- Phenylalanine-based lat1 inhibitors and uses thereof16 Oct 2025US 2025/0319046 A1Maxymune Therapeutics, Inc.
- Novel small molecule inhibitors of tead transcription factors17 Apr 2025US 2025/0122194 A1The General Hospital Corporation
- Remodilins to prevent or treat cancer metastasis, glaucoma, and hypoxia19 Dec 2024US 2024/0415851 A1Beth Israel Deaconess Medical Center, Inc.
Most cited
By later US patents
- Aryl and heteroaryl compounds, compositions and methods of use99US 7,501,538 B2TransTech Pharma, Inc. · 2009
- Aryl and heteroaryl compounds, compositions, and methods of use94US 7,459,472 B2TransTech Pharma, Inc. · 2008
- Inhibitors of histone deacetylase91US 6,541,661 B1MethylGene Inc. · 2003
- Photographic element and process comprising a compound which comprises two timing groups in sequence90US 4,861,701 AEastman Kodak Company · 1989
- 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors87US 6,310,060 B1Warner-Lambert Company · 2001